Home » Stocks » MYOV

Myovant Sciences Ltd. (MYOV)

Stock Price: $17.81 USD -0.25 (-1.38%)
Updated Apr 19, 2021 11:21 AM EDT - Market open
Market Cap 1.64B
Revenue (ttm) 34.71M
Net Income (ttm) -238.68M
Shares Out 90.80M
EPS (ttm) -2.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $17.81
Previous Close $18.06
Change ($) -0.25
Change (%) -1.38%
Day's Open 18.18
Day's Range 17.63 - 18.62
Day's Volume 226,815
52-Week Range 10.58 - 30.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Myovant (MYOV) and Pfizer (PFE) initiate dosing in the phase III SERENE study evaluating the contraceptive efficacy of the relugolix combination tablet.

Other stocks mentioned: PFE
5 days ago - Zacks Investment Research

BASEL, Switzerland and NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 SER...

1 week ago - GlobeNewsWire

BASEL, Switzerland, April 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Lauren Mer...

2 weeks ago - GlobeNewsWire

BASEL, Switzerland, March 29, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Medicines Agency...

3 weeks ago - GlobeNewsWire

Myovant (MYOV) and partner Pfizer report positive data from the phase III LIBERTY study evaluating relugolix combination therapy for treating women with uterine fibroids.

3 weeks ago - Zacks Investment Research

Myovant Sciences Ltd (NYSE: MYOV) and Pfizer Inc (NYSE: PFE) have announced positive data from the Phase 3 LIBERTY randomized withdrawal study evaluating relugolix combination therapy in women with uter...

Other stocks mentioned: PFE
3 weeks ago - Benzinga

BASEL, Switzerland and NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced positive data from the Phase 3 LIBERTY randomized withdrawal...

3 weeks ago - GlobeNewsWire

BASEL, Switzerland, March 23, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the four recipients of its Fo...

3 weeks ago - GlobeNewsWire

BASEL, Switzerland, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to li...

1 month ago - GlobeNewsWire

•LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline •Achieved six of seven key secondary endpoints including reduct...

2 months ago - GlobeNewsWire

BASEL, Switzerland and NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced publication in the New England Journal of Medicine  of the Ph...

2 months ago - GlobeNewsWire

BASEL, Switzerland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards...

2 months ago - GlobeNewsWire

RED BANK, N.J. and BASEL, Switzerland, Feb. 16, 2021 (GLOBE NEWSWIRE) -- HealthyWomen, the nation's leading independent, nonprofit health information source for women, and Myovant Sciences (NYSE: MYOV),...

2 months ago - GlobeNewsWire

Shares of Myovant Sciences (NYSE:MYOV) moved higher by 0.3% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 9.89% year over year to ($0.82), whi...

2 months ago - Benzinga

Myovant Sciences (MYOV) delivered earnings and revenue surprises of 7.87% and 27.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

BASEL, Switzerland, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and financia...

2 months ago - GlobeNewsWire

BASEL, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and con...

2 months ago - GlobeNewsWire

•84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year•Data to be included in New Drug Application submission to U...

2 months ago - GlobeNewsWire

BASEL, Switzerland and NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 SPIRIT long-term extension study of the inve...

2 months ago - GlobeNewsWire

BASEL, Switzerland, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards...

2 months ago - GlobeNewsWire

Over halfway through the trading day on Wednesday, and the broad markets are making a run into the afternoon.

Other stocks mentioned: TSLA, AMRS, C, GS, JPM, KDP, MDB ...
3 months ago - 24/7 Wall Street

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Myovant Sciences (NYSE: MYOV), please note that in the first paragraph of the release, ...

3 months ago - GlobeNewsWire

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief execut...

3 months ago - GlobeNewsWire

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™ (relugolix), the...

3 months ago - GlobeNewsWire

NEW YORK and LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., the majority shareholder of Myovant Sciences (NYSE: MYOV),  announced today that Myovant Sciences, a healthcare company ...

3 months ago - GlobeNewsWire

BASEL, Switzerland, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of David Marek...

3 months ago - GlobeNewsWire

Myovant Sciences (MYOV) and Pfizer enter collaboration agreement to develop and commercialize relugolix monotherapy and combination regimen for prostate cancer and uterine fibroids, respectively.

Other stocks mentioned: PFE
3 months ago - Zacks Investment Research

Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple scleros...

Other stocks mentioned: AYTU, KNTE, OSMT
3 months ago - Benzinga

Shares of Myovant surged as much as 35% to $30 on Monday after the biopharmaceutical company announced a partnership with Pfizer to develop and commercialize a drug for the treatment of prostate cancer ...

Other stocks mentioned: PFE
3 months ago - Business Insider

Shares of Myovant Sciences soared 27% Monday, after its parent Sumitovant Biopharma unveiled an agreement with Pfizer Inc. to jointly develop a treatment for prostate cancer and women's health in a deal...

Other stocks mentioned: PFE
3 months ago - Market Watch

Investors are cheering a big collaboration with Pfizer.

3 months ago - The Motley Fool

Myovant Sciences Ltd. (NYSE: MYOV) shares shot up on Monday after the company announced a new collaboration with the pharmaceutical giant Pfizer Inc.

Other stocks mentioned: PFE
3 months ago - 24/7 Wall Street

Myovant Sciences Ltd (NYSE: MYOV) stock is adding about one-fourth of its market capitalization Monday following a licensing deal with Pfizer Inc. (NYSE: PFE). What Happened: Myovant announced a collabo...

Other stocks mentioned: PFE
3 months ago - Benzinga

The shares of Myovant Sciences Ltd (NYSE:MYOV) are up 27.2% at $29.08 at last check, gapping to record highs, after the biopharmaceutical concern announced a collaboration with Pfizer (PFE) to develop a...

Other stocks mentioned: PFE
3 months ago - Schaeffers Research

Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada

Other stocks mentioned: PFE
3 months ago - GlobeNewsWire

Shares of Myovant Sciences soared 16% in premarket trade Monday, after its parent Sumitovant Biopharma said Myovant will work with Pfizer Inc. to jointly develop a treatment for men's and women's cancer...

Other stocks mentioned: PFE
3 months ago - Market Watch

Myovant and Pfizer to jointly develop and commercialize ORGOVYXTM (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and CanadaMyovant to receive an upfront payment ...

Other stocks mentioned: PFE
3 months ago - GlobeNewsWire

BASEL, Switzerland and NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize relugolix – a on...

3 months ago - GlobeNewsWire

Riding strong data, Myovant recently secured FDA approval for relugolix in treating advanced prostate cancer. Under the brand Orgovyx, Myovant will market the said drug as soon as in January.

3 months ago - Seeking Alpha

•ORGOVYX is the first approved therapy in the Sumitovant Biopharma family of companies •ORGOVYX is the first approved therapy in the Sumitovant Biopharma family of companies

4 months ago - GlobeNewsWire

BASEL, Switzerland, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the U.S. Food and Drug Ad...

4 months ago - GlobeNewsWire

Investors need to pay close attention to Myovant Sciences (MYOV) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

BASEL, Switzerland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to li...

4 months ago - GlobeNewsWire

BASEL, Switzerland, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards...

5 months ago - GlobeNewsWire

Myovant Sciences' (MYOV) CEO Lynn Seely on Q2 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Shares of Myovant Sciences (NYSE:MYOV) rose 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 5.06% over the past year to ($0.75), which missed ...

5 months ago - Benzinga

BASEL, Switzerland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and financia...

5 months ago - GlobeNewsWire

As you know, Myovant's shares recently tumbled due to ambiguous Phase 3 data release for its prostate cancer franchise. Upon closer inspection, I believe that relugolix will ultimately be FDA-approved f...

5 months ago - Seeking Alpha

Myovant has positive Phase 3 results in all 3 indications for its main drug relugolix. The stock has taken a huge dive based on disappointing results on a secondary endpoint of the relugolix Phase 3 pro...

5 months ago - Seeking Alpha

BASEL, Switzerland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and con...

5 months ago - GlobeNewsWire

About MYOV

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility ... [Read more...]

Industry
Biotechnology
IPO Date
Oct 27, 2016
Stock Exchange
NYSE
Ticker Symbol
MYOV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for MYOV stock is "Buy." The 12-month stock price forecast is 37.50, which is an increase of 110.56% from the latest price.

Price Target
$37.50
(110.56% upside)
Analyst Consensus: Buy